Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Liraglutide Phase III Diabetes Program Delayed Until 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo Nordisk expects its glucagon-like peptide-1 analog liraglutide to enter Phase III trials in 2005

You may also be interested in...

GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon

The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.

AstraZeneca's Galida Filing Delayed Until 2007 Due To PPAR Safety Concerns

Long-term patient follow-up is extended to two years in light of regulatory concerns about PPAR class safety, firm tells analysts. News is setback for AstraZeneca's near-term cardiovascular pipeline and a boost for Bristol/Merck's muraglitazar.

U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says

The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts